The BBD/AH-BC model predicts the risk of developing future breast cancer for women after a breast biopsy showing benign findings, including atypical hyperplasia. The result of the model can be used to help providers and patients choose among options for surveillance and prevention of breast cancer.
This calculator is intended for use by health care providers. The results should not be used alone to determine medical treatment. This tool is a statistical model and is not a substitute for an individual treatment plan developed by a health care provider with personal knowledge of a specific patient. Factors such as medical history and the health care provider’s experience, knowledge, and training must also be considered. Results should be discussed with patients when presenting prognoses or treatment recommendations.
Please choose from the following categories.
The biopsy did not contain any of the lesions listed under AH or PDWA above, but did contain at least one of the following:
The biopsy did not contain any of the lesions listed under AH above but did contain at least one of the following:
The biopsy contained at least one of the following lesions:
None indicates no involuted terminal duct lobular units (TDLUs) are involuted; partial indicates 1-74% TDLUs are involuted; complete indicates >75% TDLUs are involuted.
45 year old patient and family history of breast cancer including the following parameters:
Details regarding the development and validation of this tool are provided in the following two manuscripts:
"Model for Individualized Prediction of Breast Cancer Risk After a Benign Breast Biopsy" (V. Shane Pankratz, Amy C. Degnim, Ryan D. Frank, Marlene H. Frost, Daniel W. Visscher, Robert A. Vierkant, Tina J. Hieken, Karthik Ghosh, Yaman Tarabishy, Celine M. Vachon, Derek C. Radisky, and Lynn C. Hartmann, Journal of Clinical Oncology 2015, 33, 923-929).
“Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia” (Amy C. Degnim, Stacey J. Winham, Ryan D. Frank, V. Shane Pankratz, William D. Dupont, Robert A. Vierkant, Marlene H. Frost, Tanya L. Hoskin, Celine M. Vachon, Karthik Ghosh, Tina J. Hieken, Jodi M. Carter, Lori A. Denison, Brendan Broderick, Lynn C. Hartmann, Daniel W. Visscher, and Derek C. Radisky, Journal of Clinical Oncology 2018, 36, 1840-1846).
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.